Shares of Divis Laboratories experienced a decline of 2.59% in today's session, with the stock price falling to Rs 5,744. The stock is a constituent of the NIFTY NEXT 50 index.
Financial Snapshot:
Here's a look at the company's recent financial performance:
Consolidated Quarterly Results:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,118.00 Crore | Rs 2,338.00 Crore | Rs 2,319.00 Crore | Rs 2,585.00 Crore | Rs 2,410.00 Crore |
| Net Profit | Rs 430.00 Crore | Rs 510.00 Crore | Rs 589.00 Crore | Rs 662.00 Crore | Rs 545.00 Crore |
| EPS | 16.20 | 19.20 | 22.20 | 24.93 | 20.49 |
Consolidated Yearly Results:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 6,969.40 Crore | Rs 8,959.83 Crore | Rs 7,767.51 Crore | Rs 7,845.00 Crore | Rs 9,360.00 Crore |
| Net Profit | Rs 1,984.29 Crore | Rs 2,960.45 Crore | Rs 1,823.38 Crore | Rs 1,600.00 Crore | Rs 2,191.00 Crore |
| EPS | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| BVPS | 350.15 | 441.82 | 480.96 | 512.11 | 564.87 |
| ROE | 21.34 | 25.24 | 14.28 | 11.78 | 14.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Consolidated Yearly Income Statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 9,360 | 7,845 | 7,767 | 8,959 | 6,969 |
| Other Income | 352 | 339 | 344 | 113 | 62 |
| Total Income | 9,712 | 8,184 | 8,112 | 9,073 | 7,031 |
| Total Expenditure | 6,794 | 6,018 | 5,742 | 5,389 | 4,365 |
| EBIT | 2,918 | 2,166 | 2,369 | 3,684 | 2,666 |
| Interest | 2 | 3 | 0 | 0 | 0 |
| Tax | 725 | 563 | 545 | 723 | 681 |
| Net Profit | 2,191 | 1,600 | 1,823 | 2,960 | 1,984 |
Consolidated Quarterly Income Statement:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 2,410 | 2,585 | 2,319 | 2,338 | 2,118 |
| Other Income | 119 | 86 | 82 | 106 | 79 |
| Total Income | 2,529 | 2,671 | 2,401 | 2,444 | 2,197 |
| Total Expenditure | 1,793 | 1,806 | 1,675 | 1,721 | 1,593 |
| EBIT | 736 | 865 | 726 | 723 | 604 |
| Interest | 3 | 1 | 0 | 1 | 0 |
| Tax | 188 | 202 | 137 | 212 | 174 |
| Net Profit | 545 | 662 | 589 | 510 | 430 |
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 1,653 | 1,261 | 2,459 | 1,911 | 1,946 |
| Investing Activities | -804 | -269 | -2,707 | -2,194 | 75 |
| Financing Activities | -799 | -799 | -797 | -532 | -34 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 50 | 193 | -1,045 | -815 | 1,987 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 53 | 53 | 53 | 53 | 53 |
| Reserves & Surplus | 14,916 | 13,518 | 12,714 | 11,675 | 9,241 |
| Current Liabilities | 1,452 | 1,278 | 1,101 | 1,195 | 1,112 |
| Other Liabilities | 511 | 621 | 570 | 450 | 367 |
| Total Liabilities | 16,932 | 15,470 | 14,438 | 13,374 | 10,774 |
| Fixed Assets | 6,464 | 5,517 | 4,934 | 4,794 | 4,414 |
| Current Assets | 10,081 | 9,675 | 9,311 | 8,351 | 6,174 |
| Other Assets | 387 | 278 | 192 | 228 | 184 |
| Total Assets | 16,932 | 15,470 | 14,438 | 13,374 | 10,774 |
| Contingent Liabilities | 1,841 | 1,432 | 736 | 1,259 | 1,107 |
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| Diluted Eps (Rs.) | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 350.15 | 441.82 | 480.96 | 512.11 | 564.87 |
| Dividend/Share (Rs.) | 20.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Face Value | 2 | 2 | 2 | 2 | 2 |
| Gross Profit Margin (%) | 41.93 | 44.59 | 34.92 | 32.42 | 35.47 |
| Operating Margin (%) | 38.26 | 41.12 | 30.50 | 27.60 | 31.17 |
| Net Profit Margin (%) | 28.47 | 33.04 | 23.47 | 20.39 | 23.40 |
| Return on Networth / Equity (%) | 21.34 | 25.24 | 14.28 | 11.78 | 14.63 |
| ROCE (%) | 27.60 | 30.25 | 17.76 | 15.26 | 18.85 |
| Return On Assets (%) | 18.41 | 22.13 | 12.62 | 10.34 | 12.93 |
| Current Ratio (X) | 5.55 | 6.99 | 8.46 | 7.57 | 6.94 |
| Quick Ratio (X) | 3.62 | 4.62 | 5.73 | 5.08 | 4.71 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 3,065.41 | 4,994.76 | 4,048.48 | 848.00 | 1,660.00 |
| Asset Turnover Ratio (%) | 64.68 | 0.74 | 0.56 | 0.52 | 0.58 |
| Inventory Turnover Ratio (X) | 3.25 | 1.44 | 1.03 | 1.05 | 2.92 |
| 3 Yr CAGR Sales (%) | 33.83 | 34.59 | 20.00 | 6.10 | 2.21 |
| 3 Yr CAGR Net Profit (%) | 50.42 | 47.94 | 15.09 | -10.20 | -13.97 |
| P/E (x) | 48.47 | 39.47 | 41.10 | 57.16 | 69.98 |
| P/B (x) | 10.37 | 9.97 | 5.88 | 6.71 | 10.22 |
| EV/EBITDA (x) | 32.23 | 28.55 | 26.10 | 34.24 | 44.96 |
| P/S (x) | 13.83 | 13.05 | 9.66 | 11.61 | 16.34 |
Divis Laboratories announced a final dividend of Rs 30 per share (1500%) on May 19, 2025, with an effective date of July 25, 2025. The company had also announced a final dividend of Rs 30 per share on May 27, 2024.
The company announced a bonus issue with ratio 1:1 on August 08, 2015, with exbonus date as September 23, 2015.
The company had a stock split on August 03, 2007, with old face value of 10 and new face value of 2.
Moneycontrol analysis on September 19, 2025, indicated a very bullish sentiment for the stock.
With the stock's last traded price at Rs 5,744, Divis Laboratories has experienced a decline of 2.59% in today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
